← Back to Search

Enzyme

Latiglutenase for Celiac Disease

Phase 2
Waitlist Available
Led By Joseph Murray, MD
Research Sponsored by Entero Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial is testing a new treatment for people with celiac disease who still have symptoms despite following a gluten-free diet. The goal is to see if this new treatment can help reduce their symptoms.

Eligible Conditions
  • Celiac Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Symptom Severity Reduction
Secondary study objectives
Health Related Quality of Life

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LatiglutenaseActive Control1 Intervention
IMGX003
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Entero TherapeuticsLead Sponsor
9 Previous Clinical Trials
327 Total Patients Enrolled
2 Trials studying Celiac Disease
53 Patients Enrolled for Celiac Disease
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,316 Previous Clinical Trials
5,547,665 Total Patients Enrolled
Immunogenics, LLCLead Sponsor
3 Previous Clinical Trials
132 Total Patients Enrolled
3 Trials studying Celiac Disease
132 Patients Enrolled for Celiac Disease

Media Library

Latiglutenase (Enzyme) Clinical Trial Eligibility Overview. Trial Name: NCT04243551 — Phase 2
Celiac Disease Research Study Groups: Placebo, Latiglutenase
Celiac Disease Clinical Trial 2023: Latiglutenase Highlights & Side Effects. Trial Name: NCT04243551 — Phase 2
Latiglutenase (Enzyme) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04243551 — Phase 2
~14 spots leftby Nov 2025